Saxenda widens the gap with Qsymia. The imminent release of large products such as Wegovy.
The domestic obesity market is expanding at a rapid pace. As demand for weight loss through pharmaceuticals increases, the market size has more than doubled in the past five years. Saxenda's quarterly sales exceeded 20 billion won and its market share approached 50%. With the imminent release of large-scale products such as Mounjaro and Wegovy, which are popular overseas, a reorganization of the market is expected in the future. According to IQVIA, a pharmaceutical research institute, on the 31st, the size of the domestic obesity treatment market in the first half of last year was 96.7 billion won, a 17.9% increase from th